COMMUNIQUÉS West-GlobeNewswire

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
14/08/2025
Implemented cost reductions extend cash runway into first half of 2027 BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage [...]
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
14/08/2025
NORCROSS, Ga., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
Stryker to participate in the 2025 Wells Fargo Securities Healthcare Conference
14/08/2025
Portage, Michigan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2025 Wells Fargo Securities Healthcare Conference on Thursday, September 4, at the Encore Boston Harbor. Andy Pierce, Group [...]
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
14/08/2025
Company and Former Cincinnati Bengals Running Back Known for the “Ickey Shuffle” Collaborate to Raise Awareness and Drive Asthma Education with Focus on Acute Attacks SAN DIEGO and CINCINNATI, Aug. 14, 2025 (GLOBE [...]
Analytics For Life Completes Clinical Study of Non-Invasive Point-of-Care Test for Elevated Pulmonary Capillary Wedge Pressure (PCWP) Using Machine Learning
14/08/2025
Study achieves primary sensitivity endpoint, advancing diagnostics for heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH) Results build on data previously presented at ACC.25 in March [...]
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
14/08/2025
Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of [...]
PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)
14/08/2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of [...]
Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
14/08/2025
Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma [...]
Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability
14/08/2025
WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing its financial results for the three months ended [...]
Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
14/08/2025
NEW HAVEN, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics , a clinical-stage biotechnology company developing a novel class of therapies called RIPTAC™ Therapeutics, today announced that the U.S. Food and [...]
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
14/08/2025
First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in Europe ONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, in the United States ISELIN, N.J., [...]
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
14/08/2025
Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 Annual Meeting of [...]
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
14/08/2025
Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in [...]
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
14/08/2025
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or [...]
Polyrizon Regains Compliance with Nasdaq Listing Requirements
14/08/2025
Ra’anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced that it has [...]
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
14/08/2025
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the [...]
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use
14/08/2025
10-minute home test enables detection of Helicobacter pylori , a leading cause of peptic ulcers, dyspepsia, and gastric cancer H. pylori linked to approximately 80% of gastric cancer cases; classified as a Class 1 [...]
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
14/08/2025
Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Aug. 14, 2025 (GLOBE [...]
Fifty 1 Labs, Inc. and The Gates Foundation Lead Largest-Ever Sickle Cell Disease Study, Unlocking Pathways for Gene-Based and Repurposed Therapies
14/08/2025
Landmark AI-driven analysis backed by The Gates Foundation sets stage for transformative treatments in one of the world's most underserved diseases VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- via IBN [...]

Pages